Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia : Children ’ s Oncology Group Study AALL 0031

@inproceedings{Schultz2015LongtermFO,
  title={Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia : Children ’ s Oncology Group Study AALL 0031},
  author={Kirk R. Schultz and Andrew Carroll and Na Heerema and W. Paul Bowman and Alexander Aledo and William B. Slayton and H N Sather and Meenakshi Devidas and Hw Zheng and S M Davies and PS Gaynon and Michael E. Trigg and Ronda Rutledge and Dorothy Jorstad and Naomi Winick and Michael J. Borowitz and Stephen P. Hunger and William L. Carroll and Bruce M. Camitta},
  year={2015}
}
We previously reported preliminary findings that post induction imatinib mesylate (340 mg/m2/ day), in combination with intensive chemotherapy, resulted in outcomes similar to blood and marrow transplant (BMT) for pediatric patients with Philadelphia chromosome-positive (Ph + ) acute lymphoblastic leukemia (ALL). We now report 5-year outcomes of imatinib plus intensive chemotherapy in 91 children (1–21 years) with and without allogeneic BMT (N = 91). We explore the impacts of additional… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Prognostic value of minimal residual disease quantification before allogeneic stem - cell transplantation in relapsed childhood acute lymphoblastic leukemia : the ALL - REZ BFM Study Group

EA Raetz, MJ Borowitz, +3 authors NJ Winick
  • J Clin Oncol
  • 2009